Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukemia.

Brian J Druker1, Stephen G O'Brien, Jorge Cortes

  • 1University of Newcastle, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same author

Introduction to the Review Series. Chronic myeloid leukemia in 2026.

Haematologica·2026
Same author

Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.

The New England journal of medicine·2026
Same author

Portrait of a Pioneer: Fred Appelbaum.

Transplantation and cellular therapy·2026
Same author

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Blood neoplasia·2026
Same author

Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

The New England journal of medicine·2026

Updated chronic myelogenous leukemia (CML) treatments include imatinib mesylate, novel agents, and stem cell transplantation. Research explores imatinib combinations and resistance mechanisms for improved patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic myelogenous leukemia (CML) treatment is rapidly evolving.
  • Imatinib mesylate demonstrates significant clinical benefits, but relapses occur, especially in advanced stages.

Purpose of the Study:

  • To review updated clinical trial data for imatinib mesylate in CML.
  • To explore novel therapeutic agents and stem cell transplantation advancements for CML.
  • To investigate imatinib combinations and resistance mechanisms.

Main Methods:

  • Review of updated results for imatinib mesylate.
  • Analysis of data on new CML therapeutic agents and their mechanisms of action.
  • Evaluation of recent stem cell transplantation data, including nonmyeloablative approaches.

Related Experiment Videos

Main Results:

  • Imatinib mesylate continues to show clinical benefits, with ongoing research into resistance and combination therapies.
  • Novel agents like farnesyl transferase inhibitors, arsenic trioxide, and decitabine show potential.
  • Stem cell transplantation, including nonmyeloablative methods, offers further treatment options.

Conclusions:

  • Combination therapies with imatinib may improve outcomes for CML patients.
  • Emerging agents and refined transplantation techniques expand CML treatment paradigms.
  • Molecular profiling aids in risk stratification for personalized CML management.